Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/S2213-2600(16)30322-8. Epub 2016 Nov 4.
Takashi Seto 2, Miyako Satouchi 3, Makoto Nishio 4, Noboru Yamamoto 5, Haruyasu Murakami 6, Naoyuki Nogami 7, Shingo Matsumoto 8, Takashi Kohno 9, Koji Tsuta 10, Katsuya Tsuchihara 8, Genichiro Ishii 11, Shogo Nomura 12, Akihiro Sato 13, Atsushi Ohtsu 14, Yuichiro Ohe 5, Koichi Goto 15
Affiliations
- PMID: 27825616
- DOI: 10.1016/S2213-2600(16)30322-8
Clinical Trial
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh et al. Lancet Respir Med. 2017 Jan.
Abstract
Background: RET rearrangements are rare oncogenic alterations in non-small-cell lung cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase inhibitor exhibiting RET kinase activity. We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC.
Methods: In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. RET-positive patients were screened using a nationwide genomic screening network of about 200 participating institutions. Primary endpoint was the independently assessed objective response in eligible patients. This study is registered with UMIN-CTR, number UMIN000010095.
Findings: Between Feb 7, 2013, and March 19, 2015, 1536 patients with EGFR mutation-negative NSCLC were screened, of whom 34 were RET-positive (2%) and 19 were enrolled. Among 17 eligible patients included in primary analysis, nine (53% [95% CI 28-77]) achieved an objective response, which met the primary endpoint. In the intention-to-treat population of all 19 patients treated with vandetanib, nine (47% [95% CI 24-71]) achieved an objective response. At the data cutoff, median progression-free survival was 4·7 months (95% CI 2·8-8·5). The most common grade 3 or 4 adverse events were hypertension (11 [58%]), diarrhoea (two [11%]), rash (three [16%]), dry skin (one [5%]), and QT prolongation (two [11%]).
Interpretation: Vandetanib showed clinical antitumour activity and a manageable safety profile in patients with advanced RET-rearranged NSCLC. Our results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy.
Funding: The Ministry of Health, Labour and Welfare of Japan and the Practical Research for Innovation Cancer Control from the Japan Agency for Medical Research and Development, AMED.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
- Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?
Drilon A. Drilon A. Lancet Respir Med. 2017 Jan;5(1):5-6. doi: 10.1016/S2213-2600(16)30369-1. Epub 2016 Nov 4. Lancet Respir Med. 2017. PMID: 27825615 No abstract available. - RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.
Rosell R, Karachaliou N. Rosell R, et al. Lancet Oncol. 2016 Dec;17(12):1623-1625. doi: 10.1016/S1470-2045(16)30557-5. Epub 2016 Nov 4. Lancet Oncol. 2016. PMID: 27825637 No abstract available. - Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC.
Lee SH, Lee JK. Lee SH, et al. Lancet Respir Med. 2017 Feb;5(2):e10. doi: 10.1016/S2213-2600(17)30010-3. Lancet Respir Med. 2017. PMID: 28145234 No abstract available.
Similar articles
- Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Nosaki K, Kohno T, Tsuta K, Nomura S, Ikeno T, Wakabayashi M, Sato A, Matsumoto S, Goto K. Yoh K, et al. Lung Cancer. 2021 May;155:40-45. doi: 10.1016/j.lungcan.2021.03.002. Epub 2021 Mar 10. Lung Cancer. 2021. PMID: 33725547 Clinical Trial. - Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K. Lee SH, et al. Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559. Ann Oncol. 2017. PMID: 27803005 Clinical Trial. - A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. Platt A, et al. BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8. BMC Cancer. 2015. PMID: 25881079 Free PMC article. Clinical Trial. - Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F. Morabito A, et al. Oncologist. 2009 Apr;14(4):378-90. doi: 10.1634/theoncologist.2008-0261. Epub 2009 Apr 6. Oncologist. 2009. PMID: 19349511 Review. - Vandetanib: in medullary thyroid cancer.
Frampton JE. Frampton JE. Drugs. 2012 Jul 9;72(10):1423-36. doi: 10.2165/11209300-000000000-00000. Drugs. 2012. PMID: 22715896 Review.
Cited by
- Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?
Elshazly AM, Xu J, Melhem N, Abdulnaby A, Elzahed AA, Saleh T, Gewirtz DA. Elshazly AM, et al. Cancers (Basel). 2024 Aug 28;16(17):2989. doi: 10.3390/cancers16172989. Cancers (Basel). 2024. PMID: 39272847 Free PMC article. Review. - Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Pellizzari G, Katrini J, Passaro A, de Marinis F. Spitaleri G, et al. Cancers (Basel). 2024 Aug 19;16(16):2877. doi: 10.3390/cancers16162877. Cancers (Basel). 2024. PMID: 39199650 Free PMC article. Review. - Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
Sasaki M, Kato D, Murakami K, Yoshida H, Takase S, Otsubo T, Ogiwara H. Sasaki M, et al. Nat Commun. 2024 Jun 5;15(1):4770. doi: 10.1038/s41467-024-49063-w. Nat Commun. 2024. PMID: 38839769 Free PMC article. - Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
Gou Q, Gou Q, Gan X, Xie Y. Gou Q, et al. Sci Rep. 2024 May 5;14(1):10317. doi: 10.1038/s41598-024-61087-2. Sci Rep. 2024. PMID: 38705930 Free PMC article. Review. - Generating Potential RET-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model.
Liu L, Zhao X, Huang X. Liu L, et al. Int J Mol Sci. 2024 Feb 17;25(4):2357. doi: 10.3390/ijms25042357. Int J Mol Sci. 2024. PMID: 38397034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous